How The Cell And Gene Therapy Market Is Taking Shape

Cell and gene therapies (C>) are reshaping disease treatment, targeting root causes at the cellular level. This innovative approach promises significant improvements for patients facing complex, life-threatening conditions. GlobalData predicts the C> market will surge to $76 billion by 2030, driven by a 43% CAGR from 2023. Oncology leads the charge, attracting substantial investment and pioneering new treatments. Blood cancer therapies, like Carvykti and Yescarta, are already demonstrating substantial market growth, though challenges remain in solid tumor treatments.

Beyond oncology, breakthroughs are evident in rare diseases, with therapies like Elevidys and Casgevy showing impressive potential, despite high costs. The CNS segment also sees rapid evolution, exemplified by Zolgensma. To fully realize this potential, addressing high costs and ensuring accessibility is crucial. Discover how the C> market is evolving and its future trajectory.

Read the full article to learn more.